论文部分内容阅读
目的探讨吸入糖皮质激素联合长效β2受体激动剂治疗中度哮喘的临床效果。方法回顾性分析我院近年来呼吸内科共96例确诊中度哮喘患者的临床资料,比较两组治疗方法的疗效差异,肺功能改善情况及不良反应。结果经过6个月的治疗,治疗组总有效率为100.0%,对照组总有效率为84.38%;两组的临床疗效经统计学分析,P<0.05,差异有统计学意义,两组之间的肺功能治疗后的差异具有统计学意义。结论采用吸入糖皮质激素联合长效β2受体激动剂,临床效果明显优于单独使用糖皮质激素,值得临床推广使用。
Objective To investigate the clinical effect of inhaled glucocorticoid combined with long-acting β2 receptor agonist in the treatment of moderate asthma. Methods The clinical data of 96 patients diagnosed with moderate asthma in our department of respiratory medicine in recent years were retrospectively analyzed. The curative effects, the improvement of pulmonary function and the adverse reactions of the two groups were compared. Results After six months of treatment, the total effective rate was 100.0% in the treatment group and 84.38% in the control group. The clinical efficacy of the two groups was statistically analyzed (P <0.05), and the difference was statistically significant The differences in lung function after treatment were statistically significant. Conclusion The combination of inhaled glucocorticoid and long-acting β2 agonist has better clinical effect than glucocorticoid alone, which is worthy of clinical promotion.